Gyeongnam Biopharma and Biowithus Jointly Develop 'COVID-19 Diagnostic Test Reagents Including Variants'
[Asia Economy Reporter Hyunseok Yoo] Gyeongnam Biopharma and Biowithus announced on the 4th that they have completed the joint development of a COVID-19 diagnostic reagent including variants.
In April of last year, Gyeongnam Biopharma signed a contract with Biowithus for the joint development of diagnostic test reagents for variant COVID-19 and conducted related research.
Recently, as variant viruses with much higher transmissibility than the existing COVID-19 have been discovered mainly in South Africa, Brazil, the United Kingdom, and Germany, Gyeongnam Biopharma proceeded with the goal of producing COVID-19 diagnostic reagents and diagnostic kits.
Hot Picks Today
!["Not Everyone Can Afford This: Inside the World of the True Top 0.1% [Luxury World]"](https://cwcontent.asiae.co.kr/asiaresize/93/2026051507261063923_1778797570.png)
"Not Everyone Can Afford This: Inside the World of the True Top 0.1% [Luxury World]"
- While All Eyes Were on Samsung and Hynix, This Company Surged 50% to New Highs in Four Days [Weekend Money]
- "Now Our Salaries Are 10 Million Won a Month" Record High... Semiconductor Boom Drives Performance Bonuses at Major Electronic Component Firms
- Blue House: "Hopes for Resolution Between Samsung Electronics Labor and Management in Post-Mediation... Will Spare No Effort to Support"
- Experts Already Watching Closely..."Target Price Set at 970,000 Won" Only Upward Momentum Remains [Weekend Money]
A company official stated, "We will do our best to prepare for the post-COVID era through the development of diagnostic test reagents with improved accuracy."
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
